Skip to main content

Published locations for ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin

User login

  • Reset your password
  • /content/esc-further-data-indicate-no-excess-heart-failure-risk-lixisenatide-or-sitagliptin
  • /familypracticenews/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure-risk
  • /internalmedicinenews/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure-risk
  • /clinicalendocrinologynews/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure
  • /diabeteshub/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure-risk
  • /ecardiologynews/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure-risk
  • /cardiology/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure-risk
  • /endocrinology/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure-risk
  • /internalmedicine/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure-risk
  • /familymedicine/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure-risk
  • /type-2-diabetes-icymi/article/102605/diabetes/esc-further-data-indicate-no-excess-heart-failure-risk